---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-25-000004"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:24:03.922922+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology reports Q4 net loss $17.6M; platform launch delayed to late 2026; headcount cut 16%

## Summary
- Q4 2024 operating expenses flat at $20.0M; FY2024 op. expenses $81.5M (+7% YoY).
- Net loss Q4 $17.6M vs $17.0M YoY; FY2024 net loss $70.8M vs $63.7M YoY.
- Proteome analysis platform commercial launch now expected late 2026 (previously undisclosed).
- Headcount reduced ~16% to extend cash runway; cash $206.3M expected to fund operations through 2027.
- Board changes: two directors not standing for re-election; Matthew McIlwain reclassified as Class I director; board size reduced to 7.

## SEC filing metadata
- accession: 0001808805-25-000004
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/naut-20250224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-25-000004
- JSON: https://secwatch.observer/filing/0001808805-25-000004.json
- Plain text: https://secwatch.observer/filing/0001808805-25-000004.txt

## Key facts
- Executive change
  Michael Altman departed as Director at Nautilus Biotechnology, Inc..
  - Action: will not stand for re-election
  - Role: Director
  source text: each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm
- Executive change
  Matthew McIlwain departed as Director at Nautilus Biotechnology, Inc..
  - Action: agreed to resign as a Class II director and to stand for election as a Class I director
  - Role: Director
  source text: Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm
- Executive change
  Vijay Pande departed as Director at Nautilus Biotechnology, Inc..
  - Action: will not stand for re-election
  - Role: Director
  source text: each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.